Hypovitaminosis D association with disease activity in relapsing remitting multiple sclerosis in Brazil

被引:6
|
作者
Becker, Jefferson [1 ]
Callegaro, Dagoberto [2 ]
Lana-Peixoto, Marco Aurelio [3 ]
Talim, Natalia [3 ]
Vidaletti, Tamara [1 ]
Correa, Marcelo de Paula [4 ]
Gomes, Irenio [1 ]
机构
[1] Pontifical Catholic Univ Rio Grande Sul PUCRS, Neuroimmunol Program, Hosp Sao Lucas, Porto Alegre, RS, Brazil
[2] Univ Sao Paulo, Hosp Clin, Multiple Sclerosis Outpatient Clin, BR-05508 Sao Paulo, Brazil
[3] Univ Fed Minas Gerais, Multiple Sclerosis Res Ctr CIEM, Belo Horizonte, MG, Brazil
[4] Fed Univ Itajuba Unifei, Nat Resources Inst, Itajuba, Brazil
关键词
Multiple sclerosis; Demyelinating inflammatory disease; Risk factor; Vitamin D; Hypovitaminosis; MS epidemiology; VITAMIN-D STATUS; RISK; HEALTH;
D O I
10.1016/j.jns.2016.02.064
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Multiple sclerosis (MS) onset is believed to result from a combination of environmental and genetic factors. A prevailing theory addresses the influence of hypovitaminosis D in the development of MS. This research aimed to study the association between vitamin D serum levels and MS, as a prognostic and risk factor for the development and progression of the disease. A cross-sectional multicenter study was conducted in patients with relapsing-remitting MS (n = 67), according to the revised McDonald criteria (2010), accompanied in three MS centers in different Brazilian states. A control group consisted of healthy volunteers (n = 61). Blood collections were carried out in late summer and late winter. This seems to be the first study of this kind in Latin America. The vitamin D serum levels for MS patients (29.63 +/- 8.08) in summer were similar to the controls (29.71 +/- 8.28); however, in winter they were lower than the healthy individuals (24.05 +/- 7.47 vs 26.56 +/- 8.01). No significant difference between the three cities was observed. No association was noted between vitamin D serum levels and gender, race and age, nor correlation of these levels with the EDSS or disease duration. In contrast, a significant association was seen between deficient vitamin D serum levels in late winter with disease activity, characterized by the onset of relapses (19.73 +/- 5.69 vs 25.30 +/- 6.22) or Gd + lesions (17.22 +/- 3.11 vs 22.79 +/- 7.22). (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:236 / 239
页数:4
相关论文
共 50 条
  • [21] POSITIVE EFFECT OF ESCITALOPRAM ON DISEASE ACTIVITY IN WOMEN WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Mitsonis, C.
    Zervas, I.
    Potagas, C.
    Dimopoulos, N.
    Psara, V.
    Gkeka, A. E.
    Papadimitriou, G.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [22] Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients
    Vogt, MHJ
    Floris, S
    Killestein, J
    Knol, DL
    Smits, M
    Barkhof, F
    Polman, CH
    Nagelkerken, L
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 155 (1-2) : 155 - 160
  • [23] A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands
    Michels, Renee E.
    Peters, Michel L.
    Schiffers, Krijn Mh
    Bouma, Paul A.
    Hengstman, Gerald I. D.
    van Munster, Caspar E. P.
    Zeinstra, Esther
    De Voer, Gert
    Krol, Marieke
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (02) : 93 - 100
  • [24] Durable effect of alemtuzumab on disease activity in patients with relapsing-remitting multiple sclerosis
    Wiendl, H.
    Arnold, D. L.
    Hupperts, R. M.
    Giovannoni, G.
    Margolin, D. H.
    Kasten, L.
    Havrdova, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 256 - 256
  • [25] Regional neuronal activity in patients with relapsing remitting multiple sclerosis
    Baumgartner, Annette
    Frings, Lars
    Schiller, Florian
    Stich, Oliver
    Mix, Michael
    Egger, Karl
    Schluh, Gisa
    Rauer, Sebastian
    Meyer, Philipp T.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 138 (06): : 466 - 474
  • [26] Treatment of relapsing remitting multiple sclerosis
    Lubetzki, C
    REVUE NEUROLOGIQUE, 2001, 157 (8-9) : 996 - 1000
  • [27] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110
  • [28] Daclizumab for relapsing remitting multiple sclerosis
    Liu, Jia
    Wang, Luning
    Zhan, Si-Yan
    Xia, Yinyin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (04):
  • [29] Myelopredominant Relapsing Remitting Multiple Sclerosis
    Tarodo, Stephanie L. M. Garcia
    Freeman, Leorah
    Samudralwar, Rohini D.
    Charron, Odelin
    Papadimitropoulos, Georgios
    Lindsey, John W.
    Lincoln, John A.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 102 - 103
  • [30] Daclizumab for relapsing remitting multiple sclerosis
    Liu, Jia
    Wang, Lu-Ning
    Zhan, Siyan
    Xia, Yinyin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):